Announcement

Collapse

WELCOME TO OUR NEW HOME!

Hello MSWorld Members,

Welcome to our new home! We hope you love it as much as we do!


we promise.

to offer current and relevant information.

to grow a community built on positive and affirming support.

to showcase member creativity.

to provide safe chat rooms.

to provide well moderated forums.


we believe that what we give as a community comes back to us.

welcome to MSWorld on this journey through a different lens. together. we are msworld.
we are. community.


We appreciate your understanding as we finalize our new home. Our arcade is still currently under construction and won’t be available for a while. Thank you for your patience while we prepare a new and improved arcade for you.

enjoy our new home.

support reimagined.
See more
See less

Cladribine approved!

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Cladribine approved!

    Another new treatment, Cladribine, was approved today.

    https://www.neurologylive.com/clinic...le%20Sclerosis

    #2
    Absolutely some of the best news EVER for pwMS!!!!!!

    It will be noted that many MSers taking oral cladribine for a few days over the course of the first two years will not need to take any more for years. Some will require additional treatments, however, many will not.

    Once MSers become familiar with this new oral I cannot imagine many choosing a different oral, including the other one approved this week, Mayzent.

    IMO, this a great leap forward in the treatment of MS with an oral!

    The following scientific article will be free for approx. another month due to the generosity of the authors. Even though it may not make much sense right now, people taking Cladribine in the future may want to have downloaded this for future reference. BTW, I would have provided a fantastic slide presentation explaining cladibine, what it is, how it is taken, etc. but it has already been pulled off the internet so please do not make the mistake of believing once something is presented on the internet it is there forever because it DEFINITELY is not.

    Potential mechanisms of action related to the efficacy and safety of cladribine

    https://www.sciencedirect.com/scienc...2?dgcid=author

    Quote... "Long-term suppression from a short-term treatment cycle
    These data suggest that as potentially pathogenic T and B cells, which repopulate slowly once cladribine treatment has been administered (Stuve et al., 2017, Ceronie et al., 2018), will recover in the presence of an environment containing CD4 T regulatory cells, and potentially CD8 T suppressor cells and B regulatory cells. This is likely to create an environment favouring the re-establishment of immune tolerance leading to long-term benefit and the lack of necessity to re-treat, unless there is disease breakthrough (Fig. 5. Comi et al., 2018, Giovannoni et al., 2018a). The durability of cladribine-induced No Evidence of Disease Activity (NEDA), will only be truly appreciated with increasing use and time. If there are similarities in disease control with alemtuzumab and HSCT then many people treated with cladribine tablets will remain disease-free for many years after treatment (Touhy et al. 2015), even once memory CD4 and B cells have reached normal levels as eventually occurs, as found with alemtuzumab, although they may have novel repertoires (Storek et al., 2004; Anderson et al., 2012, Soelberg-Sorensen et al., 2017, Cooles et al., 2016). Although some of these ideas presented here are speculative, based on similarities with other DMT, they provide a framework for hypothesis-driven testing of the concepts that will help clarify the mechanism of action of cladribine further." End Quote

    Please understand the implications of the sections I highlighted. Cladribine diminishes MS while allowing your immune system to recover and function more normally (not unlike HSCT or alemtuzumab in that respect but a great deal safer than either of those) than with other MS drugs. The implication is that a more normally functioning immune system will provide the opportunity for better health.

    Comment


      #3
      Originally posted by Myoak View Post
      Absolutely some of the best news EVER for pwMS!!!!!!

      It will be noted that many MSers taking oral cladribine for a few days over the course of the first two years will not need to take any more for years. Some will require additional treatments, however, many will not.

      Once MSers become familiar with this new oral I cannot imagine many choosing a different oral, including the other one approved this week, Mayzent.

      IMO, this a great leap forward in the treatment of MS with an oral!

      The following scientific article will be free for approx. another month due to the generosity of the authors. Even though it may not make much sense right now, people taking Cladribine in the future may want to have downloaded this for future reference. BTW, I would have provided a fantastic slide presentation explaining cladibine, what it is, how it is taken, etc. but it has already been pulled off the internet so please do not make the mistake of believing once something is presented on the internet it is there forever because it DEFINITELY is not.

      Potential mechanisms of action related to the efficacy and safety of cladribine

      https://www.sciencedirect.com/scienc...2?dgcid=author

      Quote... "Long-term suppression from a short-term treatment cycle
      These data suggest that as potentially pathogenic T and B cells, which repopulate slowly once cladribine treatment has been administered (Stuve et al., 2017, Ceronie et al., 2018), will recover in the presence of an environment containing CD4 T regulatory cells, and potentially CD8 T suppressor cells and B regulatory cells. This is likely to create an environment favouring the re-establishment of immune tolerance leading to long-term benefit and the lack of necessity to re-treat, unless there is disease breakthrough (Fig. 5. Comi et al., 2018, Giovannoni et al., 2018a). The durability of cladribine-induced No Evidence of Disease Activity (NEDA), will only be truly appreciated with increasing use and time. If there are similarities in disease control with alemtuzumab and HSCT then many people treated with cladribine tablets will remain disease-free for many years after treatment (Touhy et al. 2015), even once memory CD4 and B cells have reached normal levels as eventually occurs, as found with alemtuzumab, although they may have novel repertoires (Storek et al., 2004; Anderson et al., 2012, Soelberg-Sorensen et al., 2017, Cooles et al., 2016). Although some of these ideas presented here are speculative, based on similarities with other DMT, they provide a framework for hypothesis-driven testing of the concepts that will help clarify the mechanism of action of cladribine further." End Quote

      Please understand the implications of the sections I highlighted. Cladribine diminishes MS while allowing your immune system to recover and function more normally (not unlike HSCT or alemtuzumab in that respect but a great deal safer than either of those) than with other MS drugs. The implication is that a more normally functioning immune system will provide the opportunity for better health.

      Comment


        #4
        This is great news for us, MSers!
        I have been openly critical of the slow rate and lack of treatments for this 'plague' ! I will continue to criticize the medical research industry until they discover treatments that restore my broken body and eliminate my accrued disabilities !
        This is my wish and prayer ! Good luck to all !

        Comment


          #5
          Here is a study update I received this morning. This looks like the potential for a good choice, although a time delay to "shake out" the unknowns is always a good idea. And as always, notice the initial price.

          https://multiplesclerosisnewstoday.c...aign=OneSignal

          Comment

          Working...
          X